A new study in JACC: Advances shows that tirzepatide lowers the risk of heart attack, death, and kidney injury more than GLP-1 drugs in adults over 40 with type 2 diabetes and obesity. The findings suggest broader real-world heart and kidney benefits for patients already living with cardiovascular disease.